Interview with Jacek Barlinski, Country Manager, Nycomed Poland
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Address: Al. Armii Ludowej 26
00-609 Warsaw
Tel: +48 22 579 66 66
Web: http://www.bms.com/pages/default.aspx
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Around the world, our medicines are helping millions of patients in their fight against such diseases as cancer, cardiovascular disease, diabetes, hepatitis B, HIV/AIDS, psychiatric disorders and rheumatoid arthritis.
Since 2002 the company has delivered nine important new products to patients with serious diseases. Two of these medicines are biologic products. Additional biologic compounds – as well as scores of other investigational medicines – are advancing through the development pipeline. Bristol-Myers Squibb is recognized as having one of the most productive pipelines in the industry.
What sets us apart? As a BioPharma leader, we believe it’s our commitment to patients with serious diseases and our focus on finding innovative medicines to combat those diseases.
And, as we make a difference in the lives of patients, we say, “Together we can prevail.”
http://www.bms.com
Bristol-Myers Squibb in Poland
Squibb Corporation opened its office in Poland in 1968, and Bristol-Myers in 1970. Since 1995 the company is operating in Poland as Bristol-Myers Squibb.
Theapeutic areas:
Oncology
Diabetes
HIV/AIDS
Hepatitis
Central Nervous System
Transplantology
Immunology
http://www.b-ms.pl
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your…
Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in…
With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market,…
Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and…
The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in…
Stretching across the heart of continental Europe, Poland is a massive bridge that links east and west, old and new, and which epitomizes a changing continent. At one time…
See our Cookie Privacy Policy Here